Each week Patientwing gathers new discoveries that change what's possible in medicine. This week, we're covering research showing that older adults can find relief from depression and anxiety by adding a daily probiotic to their existing antidepressant medications, a surprising finding that GLP-1 drugs like Ozempic may reduce impulsive and violent behavior, a breakthrough copper-based drug that cleared toxic Alzheimer's proteins and restored memory in lab models, and a long-term Yale study that flips one of the biggest assumptions about aging on its head. Here is what researchers found.
The idea that bacteria in your gut influence your mood has moved from hypothesis to clinical science. A pilot clinical trial published June 17, 2026 in the Journal of the American Geriatrics Society provides the most direct evidence yet that targeting the gut-brain connection through probiotics can actually work in older adults with depression.
The trial included 58 older adults with moderate depression who were already on standard antidepressant medications. Half received a daily probiotic supplement added to their standard treatment, while the other half received a placebo alongside their medications. Both groups showed substantial improvements over the 12-week trial. But the probiotic group showed meaningfully greater benefit.
Participants who took the probiotic experienced modest but clinically meaningful reductions in both depressive and anxiety symptoms beyond what their antidepressants alone had achieved. This is important because it suggests a new door: when standard treatments aren't providing enough relief, a simple daily supplement targeting the gut microbiome might offer additional help.
The mechanism is not fully understood, but researchers point to the gut-brain axis, a two-way communication system between the intestines and the nervous system. The bacteria in our gut produce neurotransmitters and metabolites that influence mood and stress response. By adding specific probiotic strains, researchers may have been able to shift that balance in a way that enhances the effects of antidepressants.
This is still early-stage evidence, and the trial was small. Researchers will need to conduct larger, longer studies to confirm the findings and identify which probiotic strains work best for which patients. But it opens a new avenue for treatment, especially for older adults who are often reluctant to add more medications when a natural supplement might help.
📰 Read more: ScienceDaily / Journal of the American Geriatrics Society, June 2026
The list of unexpected benefits from GLP-1 medications just got longer. A study published June 17, 2026 in the journal Criminology found that people taking medications like Ozempic and Wegovy showed a weaker connection between impulsivity, alcohol use, and violent behavior compared to those not taking the drugs.
Researchers at Rutgers University analyzed survey data from a nationally representative group of more than 7,500 U.S. adults collected in mid-2025. About 800 of those had used GLP-1 medications at some point, with around 600 currently taking them and 200 having stopped.
The results were striking. Among current GLP-1 users, the well-established link between impulsivity and violent behavior was substantially weaker compared to former users and non-users. The same pattern held for the relationship between alcohol use and violence. In both cases, the effects were much less pronounced in people currently taking the drugs.
Researchers think the mechanism may involve how GLP-1 drugs affect the brain's reward and impulse control centers. These medications are known to reduce dopamine-driven cravings and impulses in areas of the brain associated with reward and decision-making. Those same neural pathways are involved in aggressive behavior and impulsive violence.
Important caveats: this is observational research, meaning it shows association, not causation. The study cannot prove that the drugs directly prevent violence. The sample of drug users was relatively small, and the data is self-reported. This is a first step, not a final answer. The researchers themselves are calling for controlled, longer-term studies before drawing firm conclusions.
Still, the finding is significant enough that it has caught the attention of clinicians and is prompting discussion about whether GLP-1 drugs might have behavioral and social benefits beyond weight loss and blood sugar control.
📰 Read more: ScienceDaily / Criminology, June 2026
For decades, the conventional wisdom in Alzheimer's research has been that copper in the brain is a problem. It builds up in the wrong places and drives the kind of cellular damage that kills neurons. So when researchers at Monash University in Australia decided to deliver more copper to the brain in laboratory models of Alzheimer's disease, the broader research community took notice. The results, published June 15 in ACS Chemical Neuroscience, were striking.
The compound, called Cu(ATSM), reduced toxic amyloid-beta proteins in the brain by 42% and improved spatial learning by 44% over just 56 days of treatment. It worked through a mechanism that researchers have been trying to target for years: the brain's natural waste-clearance system.
Here is how it works. Alzheimer's disease is driven by the buildup of amyloid-beta, a sticky protein that clumps into plaques. In a healthy brain, these proteins get pumped out into the bloodstream through specialized clearance pumps embedded in the blood-brain barrier. The most important of these is called P-glycoprotein, or P-gp. In Alzheimer's disease, these clearance pumps weaken significantly, leaving the toxic proteins trapped in the brain.
The Cu(ATSM) compound restored those P-gp pumps. By increasing their abundance by 24%, it effectively unclogged the brain's drain, allowing the toxic proteins to flow out the way they were supposed to.
There is another reason this finding is generating buzz. Cu(ATSM) has already been tested in humans for two other neurological conditions, Parkinson's disease and ALS. That existing safety data could significantly shorten the path to clinical trials for Alzheimer's. Most experimental drugs spend years in early safety testing before they can even begin to look at efficacy in patients. This compound has cleared that hurdle.
It is important to note this is still preclinical work, conducted in laboratory mouse models of Alzheimer's. No human trial for the compound's use in Alzheimer's has been announced yet, and there is a long path between promising lab results and approved treatments. But for a disease where most experimental therapies have either failed outright or shown only modest benefits, a result of this magnitude is worth paying attention to.
📰 Read more: ScienceDaily / ACS Chemical Neuroscience, June 2026
The standard story about aging is that it's a steady decline. You hit your peak somewhere in middle age, and after that, your body and mind gradually wind down. A major new study from Yale University, published June 21, 2026 in the journal Geriatrics, is challenging that assumption with hard data.
Researchers analyzed more than a decade of information from the Health and Retirement Study, a federally supported, nationally representative survey of older Americans. They followed over 11,000 adults aged 65 and older for up to 12 years. They measured cognitive function using standard performance tests and physical function using walking speed, a widely accepted clinical biomarker linked to disability, hospitalization risk, and mortality.
What they found upends the conventional narrative. Nearly half, around 45%, of adults aged 65 and older showed measurable improvements in cognitive function, physical function, or both over the study period. Not stayed the same. Improved.
This doesn't mean aging is universally pleasant or that physical and cognitive challenges aren't real. But it does mean improvement after 65 is far more common than most people assume.
Even more interesting, the researchers found that beliefs about aging itself appeared to influence outcomes. Participants who held more positive views about aging were significantly more likely to show improvement in both cognition and walking speed over time. The effect held up even after accounting for age, sex, education, chronic disease, and other factors. The researchers think positive age beliefs may lead to behaviors that support healthy aging, including more physical activity, better stress management, and stronger social engagement.
The lead researcher, Dr. Becca Levy from the Yale School of Public Health, has spent her career studying how cultural attitudes toward aging shape health outcomes. Her message is that the deterministic narrative many people carry about aging may be holding them back from outcomes that are actually within reach.
📰 Read more: ScienceDaily / Geriatrics, June 2026
This week’s research focuses on what we can actually change. From probiotics supporting mental health and GLP-1s shifting behavior, to a copper compound aiding brain clearing and a Yale study challenging the assumptions of aging, each story proves what is still possible. Crucially, each of these discoveries is only possible because someone said "yes" to a clinical trial. Learn more about participating through our clinical research hub. See you next week for another edition of The Weekly Wing.
